Phospho-ERBB3 (Tyr1328) Antibody

What is Phospho-ERBB3 (Tyr1328) Antibody and what does it detect?

Phospho-ERBB3 (Tyr1328) antibody specifically detects endogenous levels of the ERBB3 (also known as HER3) protein only when phosphorylated at tyrosine residue 1328. This antibody recognizes a post-translational modification that occurs during receptor activation processes. The antibody is typically produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr1328 of human HER3/ErbB3 protein . The specificity is crucial for distinguishing between the inactive and active states of the receptor tyrosine kinase. Importantly, the antibody detects this phosphorylation site in both human and mouse samples, making it versatile for various experimental models . Phosphorylation at this site is significantly associated with downstream signaling activities and occurs during ligand-induced receptor activation.

What are the recommended applications for Phospho-ERBB3 (Tyr1328) Antibody?

Phospho-ERBB3 (Tyr1328) antibodies are validated for multiple research applications, though the specific applications may vary between different commercial antibodies. Most commonly, these antibodies are recommended for Western Blotting (WB) with a typical dilution range of 1:1000 . They are also frequently used for Immunoprecipitation (IP) with a dilution of approximately 1:100 . Additional validated applications include Immunohistochemistry (IHC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA) . The antibody has demonstrated sensitivity for detecting endogenous levels of phosphorylated HER3/ErbB3 protein in various experimental setups. Based on available data, the molecular weight of the detected protein is approximately 185 kDa . For optimal results, researchers should conduct preliminary dilution tests when applying the antibody to new experimental systems or protocols.

How can I optimize experimental conditions for detection of phosphorylated ERBB3?

Optimizing detection of phosphorylated ERBB3 requires careful attention to sample preparation and experimental conditions. When stimulating cells to induce ERBB3 phosphorylation, consider using recombinant neuregulin-1 (NRG1/HRG1) at 300 ng/mL for approximately 5 minutes, as this has been demonstrated to effectively induce phosphorylation . Immediately after stimulation, samples should be processed rapidly to preserve phosphorylation status, preferably using phosphatase inhibitors in lysis buffers. For Western blotting applications, reducing conditions and appropriate immunoblot buffer groups are recommended . When processing tissue samples, fixation methods should be optimized to preserve phosphoepitopes. For immunohistochemistry applications, a dilution range of 1:100-1:300 is typically suggested, while immunofluorescence may require a more concentrated antibody (1:50-1:200) . Fresh sample preparation and the avoidance of repeated freeze-thaw cycles of both samples and antibody reagents will help maintain signal integrity and reduce background.

How can I use Phospho-ERBB3 (Tyr1328) Antibody to investigate receptor dynamics in cancer models?

Investigating ERBB3 receptor dynamics in cancer models requires sophisticated experimental approaches that leverage the specificity of Phospho-ERBB3 (Tyr1328) antibodies. For receptor internalization studies, researchers can combine this antibody with cell surface biotinylation assays followed by immunoprecipitation to track phosphorylated receptor movement from membrane to intracellular compartments over time. Ligand-induced receptor degradation can be monitored by treating cells with neuregulin, then performing time-course western blotting with both phospho-specific and total ERBB3 antibodies to distinguish between dephosphorylation and actual protein degradation . When investigating tumor models, the antibody can detect activation states of ERBB3 in xenograft sections using immunohistochemistry, revealing spatial phosphorylation patterns within the tumor microenvironment. For mechanistic studies, pair the phospho-antibody with inhibitors of receptor trafficking pathways to elucidate the relationship between phosphorylation at Tyr1328 and receptor fate determination. Importantly, research has shown that antibodies targeting the extracellular domain of HER3 can induce receptor internalization and degradation, suggesting that monitoring Tyr1328 phosphorylation status could serve as a valuable readout for therapeutic antibody efficacy .

What is the functional significance of Tyr1328 phosphorylation compared to other ERBB3 phosphorylation sites?

Tyr1328 phosphorylation represents one of several critical regulatory phosphorylation sites on ERBB3 with distinct functional implications. This site is part of the C-terminal tail of ERBB3 and becomes phosphorylated following ligand binding and receptor dimerization. While multiple tyrosine phosphorylation sites on ERBB3 (including Y1289, Y1262, and Y1328) can recruit the p85 regulatory subunit of PI3K, they may do so with different affinities and kinetics, potentially resulting in different signaling outcomes . Tyr1328 phosphorylation specifically has been identified as functionally significant through phosphoproteomics approaches using LC-MS/MS platforms for phosphorylation site discovery . Unlike some other receptor tyrosine kinases, ERBB3 has impaired kinase activity and relies on heterodimerization with other ERBB family members for phosphorylation. Therefore, Tyr1328 phosphorylation can serve as an indicator of active ERBB2-ERBB3 or EGFR-ERBB3 heterodimers. Research has demonstrated that phosphorylation patterns across different tyrosine residues may vary depending on the dimerization partner, providing a molecular fingerprint of specific receptor activation states that could be critical for understanding divergent signaling outcomes.

How can I differentiate between heregulin-dependent and heregulin-independent ERBB3 activation?

Distinguishing between heregulin-dependent and heregulin-independent ERBB3 activation is crucial for understanding complex cancer signaling networks. For heregulin-dependent activation, stimulate cells with recombinant heregulin (NRG1-β/HRG1-β) at 300 ng/mL for short durations (5 minutes is typically sufficient) and monitor Tyr1328 phosphorylation via western blotting . This establishes your baseline ligand-induced response. For heregulin-independent activation, which often occurs in HER2-overexpressing cancer cells, examine phosphorylation status in serum-starved conditions without exogenous ligand stimulation. Colony formation assays can be particularly informative, as they have demonstrated that HER2-overexpressing tumor cell lines can form colonies in a heregulin-independent manner, which can be inhibited by HER3-targeting antibodies . To definitively separate these mechanisms, combine Phospho-ERBB3 (Tyr1328) antibody detection with neutralizing antibodies against heregulin or use HER2-specific inhibitors (such as lapatinib) to block HER2-mediated transphosphorylation. RNA interference targeting heregulin in autocrine-driven models can further help distinguish between these activation modes. Time-course experiments are also valuable, as heregulin-dependent activation typically shows rapid kinetics while heregulin-independent mechanisms may exhibit more sustained phosphorylation profiles.

What are the technical considerations for using Phospho-ERBB3 (Tyr1328) Antibody in therapy response monitoring?

Monitoring therapy response using Phospho-ERBB3 (Tyr1328) Antibody requires careful technical considerations to generate reliable data. When evaluating targeted therapies, establish baseline phosphorylation levels before treatment, then monitor changes at strategic timepoints that capture both immediate signaling inhibition (hours) and adaptive responses (days). Tissue or cell processing must be standardized and rapid, as phosphorylation status can change quickly ex vivo. For patient-derived samples, immediate fixation or snap-freezing is essential. When analyzing xenograft tissues, consider using a carrier-free antibody version to avoid potential interference from BSA or other carriers in complex microenvironments . Quantitative analysis using digital imaging and normalization to total ERBB3 expression is recommended for accurate interpretation of phosphorylation changes. Since ERBB3 reactivation has been implicated in resistance to EGFR and HER2-targeted therapies, monitor Tyr1328 phosphorylation alongside other members of the ERBB family to detect compensatory signaling. In tumors exhibiting heterogeneous response, combine phospho-specific immunohistochemistry with spatial analysis techniques to map resistance regions within the tumor architecture. Research has demonstrated that inhibition of HER3 phosphorylation correlates with reduced downstream signaling and tumor growth inhibition, making this a valuable biomarker for therapeutic response .

What are the best practices for sample preparation to detect Phospho-ERBB3 (Tyr1328)?

Optimal sample preparation is critical for reliable detection of phosphorylated ERBB3 at Tyr1328. Cells should be lysed in buffers containing both phosphatase inhibitors (sodium orthovanadate, sodium fluoride, and β-glycerophosphate) and protease inhibitors to preserve the phosphorylation status. For adherent cell cultures, direct lysis on the plate minimizes handling time and phosphorylation loss. When working with tissues, snap-freezing in liquid nitrogen followed by homogenization in cold lysis buffer yields the best results. For immunohistochemistry applications, formalin-fixed paraffin-embedded (FFPE) samples should undergo optimized antigen retrieval procedures, typically using citrate buffer pH 6.0 or EDTA buffer pH 9.0, to expose the phosphoepitope without destroying it . For immunofluorescence, 4% paraformaldehyde fixation followed by permeabilization with 0.1-0.5% Triton X-100 is generally recommended. Sample storage conditions also impact phosphoepitope stability; lysates should be aliquoted to avoid freeze-thaw cycles and stored at -80°C. For quantitative applications, prepare a standard curve using cell lysates with known phosphorylation status (untreated versus heregulin-stimulated) to ensure measurements fall within the linear detection range of the assay system.

How can I validate the specificity of Phospho-ERBB3 (Tyr1328) antibody detection in my experiments?

Validating antibody specificity is essential for generating reliable data with Phospho-ERBB3 (Tyr1328) antibodies. To confirm phospho-specificity, compare detection between unstimulated samples and those treated with heregulin (NRG1/HRG1) to induce phosphorylation . Treatment with lambda phosphatase should eliminate signal if the antibody is truly phospho-specific. For peptide competition assays, pre-incubate the antibody with the phosphopeptide immunogen to block specific binding sites; this should substantially reduce or eliminate signal. Genetic validation using ERBB3 knockout or knockdown models provides compelling evidence of specificity, and should result in loss of the 185 kDa band in western blots . Site-directed mutagenesis of Tyr1328 to phenylalanine (Y1328F) in an ERBB3 expression construct will further validate site-specificity when expressed in appropriate cellular backgrounds. For cross-reactivity assessment, test the antibody against related phosphorylated ErbB family members (EGFR, HER2, HER4) to ensure it doesn't detect similar phosphotyrosine motifs in these proteins. Finally, correlation between multiple detection methods (western blot, immunoprecipitation, immunohistochemistry) using the same antibody on identical samples increases confidence in specificity and provides technical validation across platforms.

What experimental controls should be included when working with Phospho-ERBB3 (Tyr1328) Antibody?

Robust experimental controls are essential when working with phospho-specific antibodies like Phospho-ERBB3 (Tyr1328). Include both positive and negative cellular controls: MDA-MB-453 breast cancer cells stimulated with neuregulin (300 ng/mL, 5 minutes) serve as an excellent positive control that has been validated in the literature . Unstimulated cells provide a baseline negative control. For inhibition controls, pretreat cells with PI3K inhibitors or ERBB family tyrosine kinase inhibitors before ligand stimulation to demonstrate signal specificity to the pathway. When performing western blots, include detection of total ERBB3 protein in parallel to normalize phosphosignal and confirm equivalent protein loading across samples. For immunohistochemistry and immunofluorescence, include secondary-only controls to identify potential background issues, and consider using a phospho-null (Y1328F) ERBB3 mutant-expressing cells as a definitive negative control. Technical replicate controls across multiple experimental days help establish reproducibility. When studying drug effects, include dose-response experiments with both short-term (minutes to hours) and long-term (days) timepoints to capture both immediate signaling changes and adaptive responses. For model validation, confirm the expression of both ERBB3 and its known dimerization partners (ERBB2, EGFR) in your experimental system before proceeding with phosphorylation studies.

How can I troubleshoot weak or absent signal when using Phospho-ERBB3 (Tyr1328) Antibody?

When encountering weak or absent signals with Phospho-ERBB3 (Tyr1328) antibody, several technical aspects should be systematically addressed. First, confirm ERBB3 expression in your model system using a total ERBB3 antibody, as low base expression will limit phospho-detection. Ensure proper sample preservation by verifying your phosphatase inhibitor cocktail efficacy and minimizing time between cell harvesting and protein denaturation. For western blotting applications, increase protein loading to 50-100 μg per lane and optimize transfer conditions for high molecular weight proteins (185 kDa), possibly using lower percentage gels (6-8%) and longer transfer times . The antibody concentration may need adjustment beyond the standard 1:1000 dilution; try a titration series from 1:500 to 1:2000 . For stimulation experiments, verify heregulin activity using a positive control cell line such as MDA-MB-453 . Antigen retrieval methods for immunohistochemistry may require optimization; test both heat-induced epitope retrieval with citrate buffer and EDTA-based methods at varying pH levels. Signal amplification systems (such as biotinyl tyramide) can enhance detection sensitivity for immunohistochemistry and immunofluorescence applications. Finally, consider that the phosphorylation may be transient or at low stoichiometry in your particular experimental conditions; synchronizing cells or using phosphatase inhibitor pretreatment may increase detectable phosphorylation levels.

How do I interpret changes in ERBB3 phosphorylation in the context of cancer drug resistance?

Interpreting ERBB3 phosphorylation changes in the context of cancer drug resistance requires careful consideration of signaling networks and adaptive responses. Increased phosphorylation at Tyr1328 following treatment with EGFR or HER2 inhibitors often indicates a compensatory bypass mechanism, as cancer cells may upregulate ERBB3 activity to maintain PI3K/AKT signaling when other ERBB receptors are blocked. When analyzing such samples, always compare phospho-ERBB3 levels normalized to total ERBB3 expression, as resistance may involve both increased phosphorylation efficiency and upregulation of receptor expression. Time-course experiments are crucial, as early transient dephosphorylation followed by rebound phosphorylation typically signals pathway reactivation and emerging resistance. Correlation with downstream signaling readouts (phospho-AKT, phospho-ERK) helps determine whether ERBB3 phosphorylation changes are functionally significant or merely passenger events. For in vivo studies, heterogeneous phosphorylation patterns within tumors may identify resistant subpopulations that require additional therapeutic targeting. Research has demonstrated that inhibition of ERBB3 phosphorylation correlates with reduced proliferation and increased survival in xenograft models, highlighting its functional importance in cancer progression . When monitoring patient samples during treatment, consider that ERBB3 phosphorylation may precede clinical progression and could serve as an early biomarker for adaptive resistance to targeted therapies.

How can I quantitatively analyze Phospho-ERBB3 (Tyr1328) levels across multiple samples?

Quantitative analysis of Phospho-ERBB3 (Tyr1328) across multiple samples requires standardized approaches to ensure comparability and statistical validity. For western blot quantification, include a standard curve of serially diluted positive control lysate (heregulin-stimulated cells) on each blot to establish the linear detection range . Always normalize phospho-signal to total ERBB3 protein rather than housekeeping controls to account for variations in receptor expression between samples. Digital image analysis using software like ImageJ or specialized immunoblot quantification programs should employ background subtraction and lane normalization features. For immunohistochemistry quantification, use digital pathology platforms that can distinguish between phospho-positive and negative cells, reporting both percentage of positive cells and staining intensity on a standardized scale. When comparing treatment groups, statistical approaches should account for both biological and technical variation; paired analyses are often more powerful when analyzing pre- and post-treatment samples from the same source. For time-course experiments, area-under-the-curve (AUC) calculations can capture both magnitude and duration of phosphorylation responses. Phosphoproteomic approaches using mass spectrometry can provide absolute quantification of phosphorylation stoichiometry at Tyr1328, though these require specialized facilities . For multi-site sample collection studies, standardize sample collection, processing times, and storage conditions to minimize pre-analytical variables that could affect phosphorylation status.

How can Phospho-ERBB3 (Tyr1328) Antibody be used to evaluate novel therapeutic approaches?

Phospho-ERBB3 (Tyr1328) antibodies provide powerful tools for evaluating novel cancer therapeutics, particularly those targeting the ERBB receptor family. When assessing direct HER3-targeting agents such as monoclonal antibodies, measure Tyr1328 phosphorylation to confirm target engagement and functional inhibition. Research has demonstrated that effective therapeutic antibodies against HER3 not only block ligand binding but also induce receptor internalization and degradation, which can be monitored through combined phosphorylation and total protein analysis . For evaluating combination therapies, establish baseline phosphorylation responses to single agents before testing combinations to identify synergistic inhibition patterns. In drug-resistant models, monitor ERBB3 phosphorylation as a potential escape mechanism; reactivation of Tyr1328 phosphorylation despite ongoing treatment often indicates compensatory signaling. High-throughput screening approaches can incorporate phospho-ERBB3 (Tyr1328) detection in cellular assays to identify novel compounds that indirectly affect HER3 activation. When testing immuno-oncology approaches, assess how changes in the immune microenvironment might modulate ERBB3 phosphorylation in tumor cells, as inflammatory cytokines can cross-activate receptor tyrosine kinase pathways. For patient-derived xenograft models, Tyr1328 phosphorylation status before and after treatment provides pharmacodynamic evidence of target modulation that can be correlated with tumor growth inhibition .

What are the implications of ERBB3 phosphorylation at Tyr1328 in different cancer types?

The implications of ERBB3 phosphorylation at Tyr1328 vary significantly across cancer types due to differences in signaling networks and cellular contexts. In HER2-amplified breast cancers, phosphorylation at Tyr1328 often indicates active HER2-HER3 heterodimers driving PI3K/AKT signaling, which is critical for cancer cell survival and proliferation. In these contexts, monitoring Tyr1328 phosphorylation can predict response to HER2-targeted therapies . In lung adenocarcinomas, particularly those with EGFR mutations, ERBB3 phosphorylation frequently occurs through EGFR-mediated transactivation and contributes to oncogenic signaling. Research has demonstrated that in tumor development, ERBB3 may function as an oncogenic unit together with other ERBB members, and ErbB2 specifically requires ErbB3 to drive breast tumor cell proliferation . In ovarian cancers, heregulin-independent phosphorylation may predominate, indicating constitutive activation through alternative mechanisms. Head and neck squamous cell carcinomas often exhibit elevated ERBB3 phosphorylation that correlates with disease progression and treatment resistance, as demonstrated in FaDu xenograft models where inhibition of HER3 signaling led to tumor growth inhibition and prolonged survival . Colorectal cancers with wild-type KRAS may rely more heavily on ERBB3 phosphorylation for downstream signaling compared to KRAS-mutant tumors, making Tyr1328 status a potential biomarker for selecting patients more likely to respond to upstream receptor inhibition.

How does phosphorylation at Tyr1328 correlate with other post-translational modifications of ERBB3?

Phosphorylation at Tyr1328 exists within a complex landscape of post-translational modifications (PTMs) that collectively regulate ERBB3 function. This phosphorylation site is one of several C-terminal tyrosine residues that become phosphorylated following receptor activation and can recruit the p85 regulatory subunit of PI3K . The temporal relationship between Tyr1328 phosphorylation and other tyrosine phosphorylation events (such as Tyr1289 and Tyr1262) provides insights into the sequential activation of downstream pathways . Research indicates that different ligands or heterodimerzation partners may induce distinct phosphorylation patterns across these sites. Beyond tyrosine phosphorylation, ERBB3 undergoes serine/threonine phosphorylation that can modulate receptor trafficking and degradation; the interplay between these modifications and Tyr1328 phosphorylation remains an active area of investigation. Ubiquitination of ERBB3 regulates receptor downregulation and typically increases following ligand-induced phosphorylation, creating a negative feedback loop. Glycosylation patterns on the extracellular domain can influence ligand binding efficiency and subsequent phosphorylation events. When designing experiments to study these relationships, consider using phosphoproteomics approaches that can simultaneously detect multiple phosphorylation sites, combined with inhibitors that target specific downstream pathways to identify feedback mechanisms. Site-directed mutagenesis studies replacing Tyr1328 with phenylalanine can help determine whether this specific phosphorylation site is necessary for subsequent modifications or serves as a priming event for additional regulatory mechanisms.